REG - AstraZeneca PLC - Result of AGM <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

27/04/2017 17:35

RNS Number : 6151D
AstraZeneca PLC
27 April 2017
27 April 2017 17:30 BST
Results of Annual General Meeting held on 27 April 2017
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 9 were passed as ordinary resolutions and resolutions 10 - 12 were passed as special resolutions.

RESOLUTION
VOTES FOR
% OF VOTES CAST
VOTES AGAINST
% OF VOTES CAST
VOTES CAST IN TOTAL 
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
VOTES WITHHELD
1
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2016
914,348,647
99.94
561,046
0.06
914,909,693
72.29
14,055,053
2
To confirm dividends 
925,733,259
99.75
2,281,327
0.25
928,014,586
73.32
950,160
3
To appoint PricewaterhouseCoopers LLP as Auditor 
925,181,852
99.71
2,679,401
0.29
927,861,253
73.31
1,103,493
4
To authorise the Directors to agree the remuneration of the Auditor
925,654,910
99.76
2,210,534
0.24
927,865,444
73.31
1,099,302
5a
To re-elect Leif Johansson as a Director
894,505,361
98.41
14,457,865
1.59
908,963,226
71.82
20,001,520
5b
To re-elect Pascal Soriot as a Director 
923,508,459
99.55
4,220,473
0.45
927,728,932
73.30
1,235,814
5c
To re-elect Marc Dunoyer as a Director
913,734,060
98.52
13,766,446
1.48
927,500,506
73.28
1,464,240
5d
To re-elect Genevive Berger as a Director
924,823,332
99.69
2,847,336
0.31
927,670,668
73.30
1,294,078
5e
To elect Philip Broadley as a Director
925,526,658
99.77
2,104,123
0.23
927,630,781
73.29
1,332,733
5f
To re-elect Bruce Burlington as a Director
924,643,428
99.68
2,996,388
0.32
927,639,816
73.29
1,324,930
5g
To re-elect Graham Chipchase as a Director
893,623,270
97.01
27,555,509
2.99
921,178,779
72.78
7,785,967
5h
To re-elect Rudy Markham as a Director
906,931,686
97.77
20,689,307
2.23
927,620,993
73.29
1,343,753
5i
To re-elect Shriti Vadera as a Director
921,267,292
99.31
6,370,592
0.69
927,637,884
73.29
1,326,862
5j
To re-elect Marcus Wallenberg as a Director
856,206,532
94.86
46,431,752
5.14
902,638,284
71.32
26,326,461
6
To approve the Annual Report on Remuneration for the year ended 31 December 2016
560,051,300
61.17
355,474,215
38.83
915,525,515
72.34
13,439,230
7
To approve the Directors' Remuneration Policy
877,620,302
96.08
35,804,933
3.92
913,425,235
72.17
15,539,511
8
To authorise limited political donations
898,169,470
97.87
19,518,267
2.13
917,687,737
72.51
11,278,009
9
To authorise the Directors to allot shares
842,959,080
91.03
83,045,083
8.97
926,004,163
73.17
2,960,583
10
To authorise the Directors to disapply pre-emption rights
922,652,653
99.48
4,785,159
0.52
927,437,812
73.28
1,526,934
11
To authorise the Company to purchase its own shares
916,489,233
98.82
10,984,147
1.18
927,473,380
73.28
1,491,366
12
To reduce the notice period for general meetings
845,957,281
91.63
77,228,645
8.37
923,185,926
72.94
5,778,819
AstraZeneca is pleased to have achieved shareholder support for all resolutions proposed at the AGM. AstraZeneca received a 96.08% binding vote approving the Remuneration Policy and a 61.17% advisory vote in favour of its Annual Report on Remuneration for the year ended 31 December 2016.
AstraZeneca engaged extensively with its major shareholders on remuneration matters during 2016 and the Remuneration Committee's proposals were based on shareholder feedback. AstraZeneca notes that its major shareholders exercised their independent judgement following this consultation, with the majority of them voting in favour of the Remuneration Report. The lower level of support for the Remuneration Report is considered to reflect concerns regarding how the AstraZeneca Investment Plan (AZIP) will be operated for the outstanding AZIP awards previously made, and the level of information given about the annual bonus plan and awards. AstraZeneca's Remuneration Committee will continue the dialogue with shareholders, as appropriate, regarding any concerns following its AGM.
Issued capital
As at 25 April 2017, the number of issued shares of the Company was 1,265,630,929 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Enquiries
Esra Erkal-Paler
UK/Global
+44 203 749 5638
Vanessa Rhodes
UK/Global
+44 203 749 5736
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, Neuroscience & Infection
+44 203 749 5711
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGPGUGPCUPMGQM